Targeting ACC for NASH resolution

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

(2021) Roberto A. Calle et al.   NATURE MEDICINE

Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases

(2020) Jingjing Cai et al.   CIRCULATION RESEARCH

Unexpected Rapid Increase in the Burden of Nonalcoholic Fatty Liver Disease in China From 2008 to 2018: A Systematic Review and Meta‐Analysis

(2019) Feng Zhou et al.   HEPATOLOGY

Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents

(2018) Leigh Goedeke et al.   HEPATOLOGY

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

(2018) Rohit Loomba et al.   GASTROENTEROLOGY

Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study

(2017) Kathryn Stiede et al.   HEPATOLOGY